Avastin, a VEGF-specific monoclonal antibody originally designed to inhibit angiogenesis (Figure 1), has recently made the headlines with both positive and negative clinical progress. At the start of May, it was approved by the FDA for use as a treatment for glioblastoma that has recurred after standard therapies, but in April a clinical trial assessing the ability of Avastin to reduce the risk of tumor recurrence in individuals with early-stage colon cancer failed to reach its endpoint.
展开▼
